Approved for the oral treatment of psoriasis, and is the only compound in clinical trials for the treatment of MS known to activate the Nrf2 pathway. Early stage research suggests that TECFIDERA has the potential to reduce the activity and impact of inflammatory cells on the central nervous system (CNS) and may induce direct cytoprotective responses in CNS cells. These effects may enhance the CNS cells’ ability to mitigate the toxic inflammatory and oxidative stress that play a role in MS pathophysiology.

The efficacy of TECFIDERA has been evaluated in two global Phase 2 clinical trials, DEFINE and CONFIRM. Results show that TECFIDERA administered two or three times daily, demonstrated efficacy across a number of critical endpoints vs. placebo at two years, as well as favorable safety and tolerability profiles.

Therapeutic Area

Neurodegenerative Diseases

Acquisition Date

May 2012